Ifosfamide and mitomycin in combination for the treatment of patients with progressive advanced non-small cell lung cancer

Howard Gurney, Edson Sydney de Campos, David Dodwell, Arvind Kamthan, Nicholas Thatcher

Research output: Contribution to journalArticleResearchpeer-review

Abstract

42 patients with progressive and advanced non-small cell lung cancer received chemotherapy comprising ifosfamide 1.5 g/m2, mesna 1.5 g/m2 and mitomycin 1.2 mg/m2 daily for 5 days. Only those patients with symptoms and progressive disease were selected for treatment. Partial response was achieved in 10 42 patients (23.8%) and stable disease in 25 42 (59.5%). The Karnofsky performance status (KP) improved in 10 42 patients (23.8%) and a subjective respiratory symptom score improved in 12 patients (28.6%). In addition 27 patients (64.3%) had stabilisation of both the KP and respiratory score following chemotherapy. These results indicate that the ifosfamide and mitomycin combination is active in non-small cell lung cancer in this selected group of patients with antitumour and symptom control activity.

LanguageEnglish
Pages565-567
Number of pages3
JournalEuropean Journal of Cancer and Clinical Oncology
Volume27
Issue number5
DOIs
Publication statusPublished - 1991
Externally publishedYes

Fingerprint

Ifosfamide
Mitomycin
Non-Small Cell Lung Carcinoma
Karnofsky Performance Status
Therapeutics
Mesna
Drug Therapy

Cite this

Gurney, Howard ; de Campos, Edson Sydney ; Dodwell, David ; Kamthan, Arvind ; Thatcher, Nicholas. / Ifosfamide and mitomycin in combination for the treatment of patients with progressive advanced non-small cell lung cancer. In: European Journal of Cancer and Clinical Oncology. 1991 ; Vol. 27, No. 5. pp. 565-567.
@article{df946c0353ce44f39e34460fc5d8ec2e,
title = "Ifosfamide and mitomycin in combination for the treatment of patients with progressive advanced non-small cell lung cancer",
abstract = "42 patients with progressive and advanced non-small cell lung cancer received chemotherapy comprising ifosfamide 1.5 g/m2, mesna 1.5 g/m2 and mitomycin 1.2 mg/m2 daily for 5 days. Only those patients with symptoms and progressive disease were selected for treatment. Partial response was achieved in 10 42 patients (23.8{\%}) and stable disease in 25 42 (59.5{\%}). The Karnofsky performance status (KP) improved in 10 42 patients (23.8{\%}) and a subjective respiratory symptom score improved in 12 patients (28.6{\%}). In addition 27 patients (64.3{\%}) had stabilisation of both the KP and respiratory score following chemotherapy. These results indicate that the ifosfamide and mitomycin combination is active in non-small cell lung cancer in this selected group of patients with antitumour and symptom control activity.",
author = "Howard Gurney and {de Campos}, {Edson Sydney} and David Dodwell and Arvind Kamthan and Nicholas Thatcher",
year = "1991",
doi = "10.1016/0277-5379(91)90218-3",
language = "English",
volume = "27",
pages = "565--567",
journal = "European Journal of Cancer and Clinical Oncology",
issn = "0277-5379",
publisher = "Pergamon Press",
number = "5",

}

Ifosfamide and mitomycin in combination for the treatment of patients with progressive advanced non-small cell lung cancer. / Gurney, Howard; de Campos, Edson Sydney; Dodwell, David; Kamthan, Arvind; Thatcher, Nicholas.

In: European Journal of Cancer and Clinical Oncology, Vol. 27, No. 5, 1991, p. 565-567.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - Ifosfamide and mitomycin in combination for the treatment of patients with progressive advanced non-small cell lung cancer

AU - Gurney, Howard

AU - de Campos, Edson Sydney

AU - Dodwell, David

AU - Kamthan, Arvind

AU - Thatcher, Nicholas

PY - 1991

Y1 - 1991

N2 - 42 patients with progressive and advanced non-small cell lung cancer received chemotherapy comprising ifosfamide 1.5 g/m2, mesna 1.5 g/m2 and mitomycin 1.2 mg/m2 daily for 5 days. Only those patients with symptoms and progressive disease were selected for treatment. Partial response was achieved in 10 42 patients (23.8%) and stable disease in 25 42 (59.5%). The Karnofsky performance status (KP) improved in 10 42 patients (23.8%) and a subjective respiratory symptom score improved in 12 patients (28.6%). In addition 27 patients (64.3%) had stabilisation of both the KP and respiratory score following chemotherapy. These results indicate that the ifosfamide and mitomycin combination is active in non-small cell lung cancer in this selected group of patients with antitumour and symptom control activity.

AB - 42 patients with progressive and advanced non-small cell lung cancer received chemotherapy comprising ifosfamide 1.5 g/m2, mesna 1.5 g/m2 and mitomycin 1.2 mg/m2 daily for 5 days. Only those patients with symptoms and progressive disease were selected for treatment. Partial response was achieved in 10 42 patients (23.8%) and stable disease in 25 42 (59.5%). The Karnofsky performance status (KP) improved in 10 42 patients (23.8%) and a subjective respiratory symptom score improved in 12 patients (28.6%). In addition 27 patients (64.3%) had stabilisation of both the KP and respiratory score following chemotherapy. These results indicate that the ifosfamide and mitomycin combination is active in non-small cell lung cancer in this selected group of patients with antitumour and symptom control activity.

UR - http://www.scopus.com/inward/record.url?scp=0025782959&partnerID=8YFLogxK

U2 - 10.1016/0277-5379(91)90218-3

DO - 10.1016/0277-5379(91)90218-3

M3 - Article

VL - 27

SP - 565

EP - 567

JO - European Journal of Cancer and Clinical Oncology

T2 - European Journal of Cancer and Clinical Oncology

JF - European Journal of Cancer and Clinical Oncology

SN - 0277-5379

IS - 5

ER -